Cost Effectiveness of Sucroferric Oxyhydroxide Compared with Sevelamer Carbonate in the Treatment of Hyperphosphataemia in Patients Receiving Dialysis, from the Perspective of the National Health Service in Scotland
Crossref DOI link: https://doi.org/10.1007/s40273-015-0320-9
Published Online: 2015-09-03
Published Print: 2015-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Gutzwiller, Florian S.
Pfeil, Alena M.
Ademi, Zanfina
Blank, Patricia R.
Braunhofer, Peter G.
Szucs, Thomas D.
Schwenkglenks, Matthias
Funding for this research was provided by:
Vifor Pharma (CH)
License valid from 2015-09-03